Program
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543
Its studies are mostly in Lymphoma, Non-Hodgkin · Leukemia, Myeloid, Acute, led by Johnson & Johnson.
Drug pageAnti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 1, since Jun 15, 20223 company-led studies, 3 open or runningNext primary completion: Jan 19, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 33 open or running | phase 1since Jun 15, 2022 | Jun 15, 2022 | Jan 19, 2028phase 1 · NCT06788509 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 15, 2022First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05424822 · 167 enrolled · United States, Australia, China and more
- Oct 25, 2024Phase 1 study in Lymphoma, Non-HodgkinNCT06660563 · 19 enrolled · Australia, Spain, Taiwan and more
- Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more
Ahead
- Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509
TargetBeta
“A fully human effector-silent Fc immunoglobulin G1 (IgG1) trispecific antibody targeting the tumor-associated antigens (TAAs) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) and cluster of differentiation 20 (CD20), and the T-cell surface antig”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more | 1 | By invitation | Jan 19, 2028 | 120 |
| NCT06660563Lymphoma, Non-Hodgkin · Australia, Spain, Taiwan and more | 1 | Active, not recruiting | Jan 19, 2026 | 19 |
| NCT05424822Lymphoma, Non-Hodgkin · United States, Australia, China and more | 1 | Active, not recruiting | Oct 31, 2025 | 167 |
How it is read
Names in the registry
- “JNJ-80948543”, 3 entries
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 2 studies
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.